# Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)

> **NCT00540423** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 23 (actual)

## Conditions studied

- Chronic Idiopathic Thrombocytopenic Purpura
- Purpura, Thrombocytopenic, Idiopathic

## Interventions

- **DRUG:** SB-497115-GR 12.5mg
- **DRUG:** SB-497115-GR 25mg
- **DRUG:** SB-497115-GR 12.5mg matching placebo
- **DRUG:** SB-497115-GR 50 mg

## Key facts

- **NCT ID:** NCT00540423
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-09
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 23 (ACTUAL)
- **Last updated:** 2011-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00540423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00540423, "Clinical Evaluation of SB-497115-GR in Chronic Idiopathic Thrombocytopenic Purpura (ITP)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00540423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*